$CRSP

CRISPR Therapeutics (CRSP) and Viking Therapeutics (VKTX) are highlighted as potential pharmaceutical stocks to buy. CRISPR's Casgevy treatment is expected to generate significant revenue in 2027, with analysts projecting revenue to grow from $40M to $156M. Viking Therapeutics is developing a monthly GLP-1 weight-loss injection and an oral pill, with analysts setting a 12-month price target of $93.11 for VKTX, a 175% increase from its current price.

Cathie Wood's Ark Invest sold shares of Palantir (PLTR) and AMD (AMD), and bought shares of Robinhood (HOOD) and Cerebras (CBRS). The trades were valued at $6.5M, $9.9M, $3.2M, and $6.5M respectively. Palantir and AMD saw recent partnerships and strong earnings, while Robinhood and Cerebras have seen market volatility.

CRISPR Therapeutics (CRSP) shares rose 19% in August following its Q2 earnings report. Sales of its blood disorder treatment Casgevy increased 78% to $76M, and the FDA expanded its approval. Revenue reached $10.2M, up from $892K a year ago, with a net loss of $91.5M. Analysts expected lower revenue and a larger loss. The company is developing treatments for hypertension and other disorders.

CRISPR Therapeutics (CRSP) reported $76M in Q2 2026 revenue from Casgevy, up 78% sequentially and 151% YoY. The company has a strong pipeline, including CTX310 for cardiovascular disease and Zugo-cel for autoimmune diseases. With $2.36B in cash and a $5.4B market cap, CRISPR has financial flexibility to advance multiple programs. Success in these areas could significantly increase its valuation by 2031, though risks remain.

Analysts at Jefferies, Evercore ISI, and BMO Capital maintained Buy ratings on Ascendis Pharma (ASND), Alnylam Pharma (ALNY), and Crispr Therapeutics (CRSP), with price targets of $330, $325.20, and $76 respectively. The consensus ratings are Strong Buy for ASND and ALNY, and Moderate Buy for CRSP, with average price targets indicating potential upside.

CRISPR Therapeutics (CRSP) stock is down 52.7% over 5 years, despite recent gains. The company presented Phase 1a data for CTX310, which may boost confidence in its drug pipeline. However, the stock is considered overvalued on market multiples, trading at a P/B of 3.2x, above the biotech industry average. Investors are paying a premium for its pipeline potential, but clinical and regulatory risks remain significant.

CRISPR Therapeutics (CRSP) presented one-year data from its Phase 1a trial of CTX310, showing significant reductions in ANGPTL3, triglycerides, and LDL. The therapy was well-tolerated. The company is advancing to Phase 1b, with an update expected in 2026.

Citizens reiterated a Market Outperform rating and $80 price target for CRISPR Therapeutics (CRSP), citing upcoming gene therapy data and potential 40% upside. The firm highlighted the company's focus on severe hypertriglyceridemia and refractory hypercholesterolemia, with a one-time therapy approach. CRISPR's label expansion for CASGEVY and Vertex Pharmaceuticals' promising data also support the positive outlook, according to Citizens.

Simply Wall St reports CRISPR Therapeutics (CRSP) drew renewed attention after it posted Q2 2026 results on Aug. 3. The company reported revenue of $10.18M and a reduced net loss of $91.15M. The stock rose 3.64% in one day and 11.52% over a week. A DCF model estimates fair value at $218.96 versus a $53.52 close.

CRISPR Therapeutics (CRSP) reported a Q2 2026 loss of 94 cents per share, narrower than the Zacks estimate of a $1.10 loss. Revenue rose to $10.2 million, above the $7 million estimate. Vertex’s Casgevy sales were $76 million in Q2. CRSP ended June with $2.36 billion cash and said multiple pipeline updates are expected in H2 2026.